William Jacot
Impact in
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 123
- HER2/EGFR in Cancer Research 39
- Cancer Treatment and Pharmacology 26
- Lung Cancer Research Studies 11
- Cancer Cells and Metastasis 11
-
- Breast Cancer Treatment Studies 29
- Cancer Genomics and Diagnostics 14
- Co-authors
- Pierre‐Jean Lamy (32 shared papers)Séverine Guiu (32 shared papers)Gilles Romieu (33 shared papers)Catherine Alix‐Panabières (12 shared papers)Simon Thézenas (28 shared papers)Florence Boissière‐Michot (19 shared papers)Caroline Mollevi (19 shared papers)Evelyne Lopez‐Crapez (18 shared papers)
- Journals
- Annals of Oncology (22 papers)BMC Cancer (12 papers)ESMO Open (12 papers)British Journal of Cancer (11 papers)European Journal of Cancer (10 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
William Jacot
234 papers receiving 12.8k citations
William Jacot's Hit Papers
Peers
Comparison fields: 5 of 139
- Oncology 6.5k
- Cancer Research 3.1k
- Pulmonary and Respiratory Medicine 2.9k
- Radiology, Nuclear Medicine and Imaging 1.4k
- Genetics 559
Countries citing papers authored by William Jacot
This map shows the geographic impact of William Jacot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Jacot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Jacot more than expected).
Fields of papers citing papers by William Jacot
This network shows the impact of papers produced by William Jacot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Jacot. The network helps show where William Jacot may publish in the future.
Co-authors
The 25 scholars most cited alongside William Jacot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 251 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Hit paper breakdown → | 2018 | 1980 |
| 2 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Hit paper breakdown → | 2022 | 1875 |
| 3 | PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer Hit paper breakdown → | 2023 | 1334 |
| 4 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 472 |
| 5 | 2015 | 324 | |
| 6 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 321 |
| 7 | Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer Hit paper breakdown → | 2024 | 263 |
| 8 | Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials Hit paper breakdown → | 2021 | 241 |
| 9 | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer Hit paper breakdown → | 2023 | 227 |
| 10 | 2018 | 220 | |
| 11 | 2004 | 162 | |
| 12 | 2019 | 162 | |
| 13 | 2009 | 147 | |
| 14 | 2013 | 146 | |
| 15 | 2020 | 145 | |
| 16 | 2020 | 138 | |
| 17 | 2020 | 137 | |
| 18 | 2021 | 127 | |
| 19 | 2021 | 123 | |
| 20 | 2022 | 121 |
About William Jacot
William Jacot is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 251 papers that have together received 13.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (39 papers), Advanced Breast Cancer Therapies (37 papers), Breast Cancer Treatment Studies (29 papers), Brain Metastases and Treatment (27 papers), Cancer Treatment and Pharmacology (26 papers), Cancer Genomics and Diagnostics (14 papers), Lung Cancer Research Studies (11 papers) and Cancer Cells and Metastasis (11 papers). The work is most often cited by research in Oncology (6.5k citations), Cancer Research (3.1k citations), Pulmonary and Respiratory Medicine (2.9k citations), Radiology, Nuclear Medicine and Imaging (1.4k citations) and Genetics (559 citations). William Jacot has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Pierre‐Jean Lamy, Séverine Guiu, Gilles Romieu, Catherine Alix‐Panabières, Simon Thézenas, Florence Boissière‐Michot, Caroline Mollevi, Evelyne Lopez‐Crapez, Laure Cayrefourcq and Klaus Pantel. Their work appears in journals such as Annals of Oncology, BMC Cancer, ESMO Open, British Journal of Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.